Compare
Atea Pharmaceuticals, Inc. vs LB Pharmaceuticals Inc vs Omeros Corp vs Prothena Corp Public Ltd Co
| Latest fiscal year | Atea Pharmaceuticals, Inc. AVIR | LB Pharmaceuticals Inc LBRX | Omeros Corp OMER | Prothena Corp Public Ltd Co PRTA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | n/a | $9.68M |
| Revenue growth (YoY) | n/a | n/a | n/a | -92.8% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | n/m |
| Net margin | n/a | n/a | n/a | n/m |
| Net income | -$158.35M | -$25.20M | -$3.35M | -$244.09M |
| EPS (Diluted) | -$1.94 | -$3.13 | -$0.05 | -$4.53 |
| Operating cash flow | -$132.03M | -$35.21M | -$116.09M | -$163.58M |
| Free cash flow | n/a | -$35.26M | -$116.16M | n/a |
| Cash & equivalents | $95.71M | $250.17M | $9.66M | $307.53M |
| Total assets | $315.22M | $312.93M | $325.63M | $326.80M |
| Total liabilities | $39.78M | $11.62M | n/a | $46.33M |
| Shareholders' equity | $275.43M | $301.31M | -$121.23M | $280.47M |
| Return on year-end equity | -57.5% | -8.4% | n/a | -87.0% |
| Shares outstanding | 78.13M | 25.30M | 71.67M | 53.83M |
Revenue, most recent five fiscal years
| Fiscal year | Atea Pharmaceuticals, Inc. | LB Pharmaceuticals Inc | Omeros Corp | Prothena Corp Public Ltd Co |
|---|---|---|---|---|
| Latest | $351.37M Ended 2021-12-31 | n/a | $73.81M Ended 2020-12-31 | $9.68M Ended 2025-12-31 |
| 1 year earlier | $48.63M Ended 2020-12-31 | n/a | $111.81M Ended 2019-12-31 | $135.16M Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | $29.87M Ended 2018-12-31 | $91.37M Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | $64.83M Ended 2017-12-31 | $53.91M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $41.62M Ended 2016-12-31 | $200.58M Ended 2021-12-31 |